The $1.125 million grant will go to support the development of new drug therapies for protecting the retina and optic nerve in chronic degenerative eye disease.
Research will be led by Peter Koulen, PhD, professor and endowed chair in vision research at the School of Medicine and director of basic research at the Vision Research Center.
“Degeneration or damage of the retina and the optic nerve — the nerve that connects the eye to the brain and makes vision possible — is a leading cause of loss of quality of life and productivity in the United States and worldwide,” said Dr. Koulen, in the releas. “The therapy approach we’re developing focuses on much-needed protection of nerve cells in the eye. The goal is to develop drug therapies that will be both preventative and therapeutic and complement existing treatment designs and rationales.”
Related Articles on Ophthalmology:
How ASCs Can Profit From Ophthalmology
Ophthalmologist Dr. William Constad to Receive ‘Man of Vision’ Honor
Ophthalmologist on the Move: Dr. George Baerveldt Joins CA’s NVISION Laser Eye Centers
Becker’s 3rd Annual Fall Chief Pharmacy Officer Summit is the top tier event that the people leading the future of pharmacy convene. This 3-day event is built specifically for Chief Pharmacy Officers and senior pharmacy leaders. The sessions examine the workforce, financial and clinical priorities shaping pharmacy today. Becker’s is where candid discussions flourish and new ideas thrive. Becker's 3rd Annual Fall Chief Pharmacy Officer Summit
